NDASUBCUTANEOUSSOLUTION
Approved
Dec 2012
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Data completeness
5/8 — Partial
SIGNIFOR (pasireotide) by Recordati is somatostatin receptor agonists [moa]. First approved in 2012.
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SIGNIFOR (pasireotide) is a somatostatin receptor agonist administered via subcutaneous injection for the treatment of acromegaly and Cushing's disease. It works by binding to somatostatin receptors to suppress growth hormone and ACTH secretion. Pasireotide offers broader somatostatin receptor subtype coverage compared to octreotide, potentially improving efficacy in some patient populations.
$0.001BPart D
LOE ApproachingDeclining
6mo to LOEDeclining spending and minimal claim volume indicate a small, niche franchise approaching patent expiration with limited team expansion opportunities.
Mechanism of Action
Somatostatin Receptor Agonists
Pharmacologic Class:
Somatostatin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule
Started Dec 2025
40 enrolled
PharmacokineticsSafety
Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
Started Dec 2024
28 enrolled
Desmoplastic Small Round Cell TumorSynovial Sarcoma
A Study of Pasireotide in People With Prolactinoma
Started Feb 2024
10 enrolled
Prolactin-Producing Pituitary Tumor
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
Started Jan 2024
93 enrolled
Post-Bariatric Hypoglycemia
Pasireotide in Hyperinsulinemic Hypoglycemia
Started Apr 2017
0Congenital HyperinsulinismInsulinomaHyperinsulinism
Worked on SIGNIFOR at Recordati? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.